Oral versus intravenous CMF in metastatic breast cancer: A randomized study

M. Brandi, A. De Mitrio, P. Ditonno, A. Catino, V. Lorusso, M. De Lena

Research output: Contribution to journalArticle

Abstract

Sixty-eight patients with previously untreated metastatic breast cancer were randomly assigned to receive either 'classical CMF' (orally administered cyclophosphamide) or new intravenous administration of all drugs every 3 weeks. Overall response rates of 44.5% (95% CI:28-62%) and 39% (95% CI:24- 54%) were observed with classical and new CMF, respectively. The time to progression and overall survival were also similar: hematologic toxicity was mild in both groups, but the tolerance and patient compliance was generally better for the new CMF. The patients treated with classical CMF received a significantly higher drug intensity; dose intensity, however, had no impact on clinical results. In conclusion, our data suggest that the new CMF schedule has comparable activity to classical CMF but better patient compliance. A brief review of recent clinical studies regarding dose-effect relationships in breast cancer is included.

Original languageEnglish
Pages (from-to)559-565
Number of pages7
JournalInternational Journal of Oncology
Volume4
Issue number3
Publication statusPublished - 1994

Fingerprint

Patient Compliance
Breast Neoplasms
Pharmaceutical Preparations
Intravenous Administration
Cyclophosphamide
Appointments and Schedules
Survival
Clinical Studies

Keywords

  • advanced breast cancer
  • intensive chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Oral versus intravenous CMF in metastatic breast cancer : A randomized study. / Brandi, M.; De Mitrio, A.; Ditonno, P.; Catino, A.; Lorusso, V.; De Lena, M.

In: International Journal of Oncology, Vol. 4, No. 3, 1994, p. 559-565.

Research output: Contribution to journalArticle

Brandi, M, De Mitrio, A, Ditonno, P, Catino, A, Lorusso, V & De Lena, M 1994, 'Oral versus intravenous CMF in metastatic breast cancer: A randomized study', International Journal of Oncology, vol. 4, no. 3, pp. 559-565.
Brandi, M. ; De Mitrio, A. ; Ditonno, P. ; Catino, A. ; Lorusso, V. ; De Lena, M. / Oral versus intravenous CMF in metastatic breast cancer : A randomized study. In: International Journal of Oncology. 1994 ; Vol. 4, No. 3. pp. 559-565.
@article{3c1c9bbc06bf405ebf149d2b18713f58,
title = "Oral versus intravenous CMF in metastatic breast cancer: A randomized study",
abstract = "Sixty-eight patients with previously untreated metastatic breast cancer were randomly assigned to receive either 'classical CMF' (orally administered cyclophosphamide) or new intravenous administration of all drugs every 3 weeks. Overall response rates of 44.5{\%} (95{\%} CI:28-62{\%}) and 39{\%} (95{\%} CI:24- 54{\%}) were observed with classical and new CMF, respectively. The time to progression and overall survival were also similar: hematologic toxicity was mild in both groups, but the tolerance and patient compliance was generally better for the new CMF. The patients treated with classical CMF received a significantly higher drug intensity; dose intensity, however, had no impact on clinical results. In conclusion, our data suggest that the new CMF schedule has comparable activity to classical CMF but better patient compliance. A brief review of recent clinical studies regarding dose-effect relationships in breast cancer is included.",
keywords = "advanced breast cancer, intensive chemotherapy",
author = "M. Brandi and {De Mitrio}, A. and P. Ditonno and A. Catino and V. Lorusso and {De Lena}, M.",
year = "1994",
language = "English",
volume = "4",
pages = "559--565",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Oral versus intravenous CMF in metastatic breast cancer

T2 - A randomized study

AU - Brandi, M.

AU - De Mitrio, A.

AU - Ditonno, P.

AU - Catino, A.

AU - Lorusso, V.

AU - De Lena, M.

PY - 1994

Y1 - 1994

N2 - Sixty-eight patients with previously untreated metastatic breast cancer were randomly assigned to receive either 'classical CMF' (orally administered cyclophosphamide) or new intravenous administration of all drugs every 3 weeks. Overall response rates of 44.5% (95% CI:28-62%) and 39% (95% CI:24- 54%) were observed with classical and new CMF, respectively. The time to progression and overall survival were also similar: hematologic toxicity was mild in both groups, but the tolerance and patient compliance was generally better for the new CMF. The patients treated with classical CMF received a significantly higher drug intensity; dose intensity, however, had no impact on clinical results. In conclusion, our data suggest that the new CMF schedule has comparable activity to classical CMF but better patient compliance. A brief review of recent clinical studies regarding dose-effect relationships in breast cancer is included.

AB - Sixty-eight patients with previously untreated metastatic breast cancer were randomly assigned to receive either 'classical CMF' (orally administered cyclophosphamide) or new intravenous administration of all drugs every 3 weeks. Overall response rates of 44.5% (95% CI:28-62%) and 39% (95% CI:24- 54%) were observed with classical and new CMF, respectively. The time to progression and overall survival were also similar: hematologic toxicity was mild in both groups, but the tolerance and patient compliance was generally better for the new CMF. The patients treated with classical CMF received a significantly higher drug intensity; dose intensity, however, had no impact on clinical results. In conclusion, our data suggest that the new CMF schedule has comparable activity to classical CMF but better patient compliance. A brief review of recent clinical studies regarding dose-effect relationships in breast cancer is included.

KW - advanced breast cancer

KW - intensive chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0028219201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028219201&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028219201

VL - 4

SP - 559

EP - 565

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -